Øjvind Lidegaard

Øjvind Lidegaard

Auto-generated profile, based on publicly available information

Øjvind Lidegaard

Rigshospitalet

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
LMLina S. Mørch
Lina S. Mørch
CSCharlotte W. Skovlund
Charlotte W. Skovlund
PHPhilip C. Hannaford
Philip C. Hannaford
LILisa Iversen
Lisa Iversen
SFShona Fielding
Shona Fielding
ØLØjvind Lidegaard
Øjvind Lidegaard
Little is known about whether contemporary hormonal contraception is associated with an increased risk of breast cancer.

31 August 2018 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
SSSimona Sacco
Simona Sacco
GMGabriele Susanne Merki-Feld
Gabriele Susanne Merki-Feld
KÆKaren Lehrmann Ægidius
Karen Lehrmann Ægidius
JBJohannes Bitzer
Johannes Bitzer
MCMarianne Canonico
Marianne Canonico
PMPaolo Martelletti
Paolo Martelletti
We systematically reviewed data about the effect of exogenous estrogens and progestogens on the course of migraine during reproductive age. Thereafter a consensus procedure among international experts was undertaken to develop statements to support clinical decision making, in terms of possible effects on migraine course of exogenous estrogens and progestogens and on possible treatment of headache associated with the use or with the withdrawal of hormones. Overall, quality of current evidence is low. Recommendations are provided for all the compounds with available evidence including the conventional 21/7 combined hormonal contraception, the desogestrel only oral pill, combined oral contraceptives with shortened pill-free interval, combined oral contraceptives with estradiol supplementation during the pill-free interval, extended regimen of combined hormonal contraceptive with pill or patch, combined hormonal contraceptive vaginal ring, transdermal estradiol supplementation with gel, transdermal estradiol supplementation with patch, subcutaneous estrogen implant with cyclical oral progestogen. As the quality of available data is poor, further research is needed on this topic to improve the knowledge about the use of estrogens and progestogens in women with migraine. There is a need for better management of headaches related to the use of hormones or their withdrawal.

1 August 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
OGOranite Goldrat
Oranite Goldrat
NKNiels Kroman
Niels Kroman
Fedro Alessandro Alessandro PeccatoriFedro Alessandro Alessandro Peccatori
Fedro Alessandro Alessandro Peccatori
Octavi CórdobaOctavi Córdoba
Octavi Córdoba
BPBarbara Pistilli
Barbara Pistilli
HAHatem A. Azim
Hatem A. Azim

26 April 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
ØLØjvind Lidegaard
Øjvind Lidegaard
AMAnders P. Mikkelsen
Anders P. Mikkelsen
PEPia Egerup
Pia Egerup
AKAstrid M. Kolte
Astrid M. Kolte
SRSteen Christian Rasmussen
Steen Christian Rasmussen
HNHenriette S. Nielsen
Henriette S. Nielsen

14 August 2014 in BMJ Open
Verified
Journal Article
Open access
PDF file
MHMette Hedegaard
Mette Hedegaard
ØLØjvind Lidegaard
Øjvind Lidegaard
CSCharlotte Wessel Skovlund
Charlotte Wessel Skovlund
LMLina Steinrud Mørch
Lina Steinrud Mørch
MHMorten Hedegaard
Morten Hedegaard
Objective The risk of fetal death increases steeply after 42 gestational weeks. Since 2009, Denmark has had a more proactive policy including prevention of prolonged pregnancy, and early intervention in women with diabetes, preeclampsia, high body mass index and of a higher age group. The aim of this study was to describe the development in fetal deaths with this more proactive birth induction practice, and to identify and quantify contributing factors for this development. Design National cohort study. Setting Denmark. Participants Delivering women in Denmark, 1 January 2000 to 31 December 2012. Outcome measures Stillbirths per 1000 women at risk (prospective risk of stillbirth) and per 1000 newborn from 37 and 40 gestational weeks, respectively, through the study period. Results During the study period, 829 165 children were live born and 3770 (0.45%) stillborn. Induction of labour increased from 12.4% in year 2000 to 25.1% in 2012 (p<0.001), and the percentage of children born at or after 42 weeks decreased from 8.0% to 1.5% (p<0.001). Through the same period, the prospective risk of stillbirth after 37 weeks fell from 0.70 to 0.41/1000 ongoing pregnancies (p<0.001), and from 2.4 to 1.4/1000 newborn (p30, twins, and of women above 40 years and a halving of smoking pregnant women were all independent contributing factors for the decrease. Conclusions A gradually more proactive and differential earlier labour induction practice is likely to have mainly been responsible for the substantial reduction in stillbirths in Denmark.

28 August 2014 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
ØLØjvind Lidegaard
Øjvind Lidegaard
This paper reviews the risk of thrombosis with use of different types of hormonal contraception in women of different ages. Combined hormonal contraceptives with desogestrel, gestodene, drospirenone or cyproterone acetate (high-risk products) confer a sixfold increased risk of venous thromboembolism as compared with nonusers, and about twice the risk as compared with users of products with norethisterone, levonorgestrel or norgestimate (low-risk products). Transdermal patches and vaginal ring belong to high-risk products. The risk of thrombotic stroke and myocardial infarction is increased 50 - 100% with use of combined products, with little difference in risk between different progestins. Progestin-only products do not confer any increased risk of venous or arterial thrombosis, except for progestin depot, which may double the risk of venous thrombosis. First choice in women below 35 years should be a combined low-risk pill, that is, with a second-generation progestin, with the lowest compliable dose of estrogen. Young women with risk factors of thrombosis such as age above 35 years, genetic predispositions, adiposity, polycystic ovary syndrome, diabetes, smoking, hypertension or migraine with aura should not use high-risk products, but should primarily consider progestin-only products, and be careful to use low-risk combined products.